111P - EGFR mutations among lung adenocarcinoma patients in Serbia - EGFR mutation incidence and its correlation with patient demographic characteristics

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Aetiology, Epidemiology, Prevention
Pathology/Molecular Biology
Presenter Bojan Zaric
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors B. Zaric1, B. Perin2, V. Kovcin3, M. Cekic4, D. Jovanovic5, D. Radosavljevic6, Z. Murtezani7, M. Rancic8, R. Jankovic9, N. Vukobradovic-Djoric10
  • 1Clinic For Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, 21204 - Sremska Kamenica/YU
  • 2Clinic For Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina, 21204 - Sremska kamenica/YU
  • 3Outpatient Chemotherapy Department, Clinical Hospital Center Bezanijska Kosa, Belgrade/YU
  • 4Pulmolology, Clinic of Lung Diseases and TB, Knez Selo/YU
  • 5Institute Of Lung Diseases, Clinical Center of Serbia, Belgrade/YU
  • 6Oncology, Institute of Oncology and Radiology of Serbia, Belgrade/YU
  • 7Oncology, Clinical Hospital Center Bezanijska Kosa, Belgrade/YU
  • 8Clinic Of Lung Diseases And Tb, Clinic of Lung Diseases and TB, Knez Selo/YU
  • 9Department Of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade/YU
  • 10Roche, Roche, Serbia, Belgrade/YU

Abstract

The detection of EGFR mutations in tumor tissues nowdays is guiding the treatment for advanced NSCLC. It is known that patients with lung adenocarcinoma have more frequent mutations, especially in population of women, non-smokers. The mutation L858R in exon 21 and the deletions in exon 19 account for >85% of all clinically important mutations.